CU
Cure Pharmaceutical Holding Corp. (CURR)
NASDAQ
3.57
-0.14 (-3.77%)
Closed
Aug 25, 2026
Day's Range
3.523.78
52 wk Range
1.314.72
Financial Statements - CURR - Cure Pharmaceutical Holding Corp.
Revenue
37.81M▼ 18.6%
Net Income
-18.50M▲ 52.3%Net Margin -48.9%
EBITDA
-13.01M▲ 51.5%
Free Cash Flow
7.38M▲ 157.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 37.81M | 46.43M | 53.25M | 55.50M | 57.50M | 61.56M |
| Cost of Goods | 22.39M | 31.84M | 35.89M | 39.88M | 39.60M | 45.57M |
| Gross Profit | 15.41M | 14.59M | 17.35M | 15.61M | 17.89M | 15.99M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -7.93M | -27.37M | -6.64M | -10.01M | 39.72K | -405.98K |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -7.30M | -2.35M | 754.03K | 2.60M | -631.97K | 1.48M |
| Pre Tax Income | -18.35M | -38.24M | -13.89M | -15.61M | -12.13M | -3.57M |
| Income Tax | 148.93K | 578.30K | 523.48K | 113.78K | 753.70K | 1.49M |
| Net Income | -18.50M | -38.82M | -14.41M | -15.72M | -12.88M | -5.06M |
| EPS Basic | -0.3 | -1.03 | -0.45 | -0.358454 | -0.319145 | -0.144524 |
| EPS Diluted | -0.3 | -1.03 | -0.45 | -0.358454 | -0.319145 | -0.144524 |
| Basic Shares Outstanding | 61.47M | 38.16M | 33.98M | 46.52M | 46.52M | 46.52M |
| Diluted Shares Outstanding | 61.47M | 38.16M | 33.98M | 46.52M | 46.52M | 46.52M |
| Ebit | -15.24M | -29.73M | -5.89M | -7.41M | -592.24K | 1.07M |
| Ebitda | -13.01M | -26.83M | -1.90M | -3.01M | 5.39M | 6.90M |
| Net Income Continuous Operations | -18.50M | -38.82M | -14.41M | -15.72M | -12.88M | -5.06M |
| Minority Interests | 72.42K | -648.55K | -888.76K | -952.42K | -1.96M | -1.65M |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
